Kairos Pharma

Kairos Pharma is a private, clinical-stage biotech focused on overcoming two major challenges in oncology: acquired drug resistance and immune suppression. Its core platform targets the CD105 protein, identified as a central mechanism of resistance to therapies in prostate and lung cancers, and develops complementary immunomodulatory technologies. With its lead asset, ENV105, in Phase 2 trials for prostate cancer and Phase 1 for lung cancer, the company is positioned to address a significant unmet need across multiple solid tumors, backed by intellectual property protection extending to 2040.

Platform focused on targeting the CD105 protein to reverse acquired resistance to standard cancer therapies (e.g., anti-androgens, EGFR inhibitors) and complementary technologies to reverse tumor-induced immune suppression.

Kairos competes in the crowded space of overcoming oncology drug resistance, facing companies developing next-generation targeted therapies, antibody-drug conjugates, and novel combination regimens. Its specific focus on CD105 is a differentiated approach, but it must compete for clinical adoption and partnership attention against numerous other mechanisms and technologies.